Apremilast, Methotrexate and <scp>NB</scp> ‐ <scp>UVB</scp> Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison
APRE, MTX, and NB-UVB each improved clinical outcomes with comparable overall efficacy and good tolerability in this pilot cohort. Each therapeutic regime showed distinct immunomodulatory profiles with good tolerability. Personalized treatment strategies, including potential combinations, may optimize outcomes for patients with moderate-to-severe psoriasis.
Authors
- Alessia Balestrino (ORCID: https://orcid.org/0009-0007-1982-7031)
- Annunziata Raimondo (ORCID: https://orcid.org/0000-0002-0849-715X)
- Serena Lembo (ORCID: https://orcid.org/0000-0001-9053-1793)
- Raffaella Manzo
- M. Battipaglia (ORCID: https://orcid.org/0000-0001-9365-8917)
- Annunziata Nigro (ORCID: https://orcid.org/0000-0002-1838-1484)
Institutions
- University of Salerno (IT)
- CTO Hospital (IT)
Publication Details
- Journal
- Photodermatology Photoimmunology & Photomedicine
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1111/phpp.70066
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00